Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth

Translational Oncology

Volumn 5, Issue 2, 2012, Pages 92-97

  Koskimaki, Jacob E ^a   Rosca, Elena V ^a   Rivera, Corban G ^a   Lee, Esak ^a,b   Chen, William ^a   Pandey, Niranjan B ^a   Popel, Aleksander S ^a,c  

^a Johns Hopkins University   (United States)

^b Johns Hopkins University   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; DEAH BOX HELICASE; HELICASE; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEOME; SERINE PROTEINASE INHIBITOR; SP 6001; SP 6023; SP 6024; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOINFORMATICS; BREAST TUMOR; CELL ADHESION; CELL MIGRATION; DRUG ACTIVITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; SEQUENCE HOMOLOGY; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84859466236     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11244     Document Type: Article

References (31)

1. Folkman J (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6, 273-286.
2. Hoshina D, Abe R, Yamagishi SI, and Shimizu H (2010). The role of PEDF in tumor growth and metastasis. Curr Mol Med 10, 292-295.
3. Tombran-Tink J (2005). The neuroprotective and angiogenesis inhibitory serpin, PEDF: new insights into phylogeny, function, and signaling. Front Biosci 10, 2131-2149.
4. Ek ET, Dass CR, and Choong PF (2006). PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med 12, 497-502.
5. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, and Distler O (2003). Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 47, 149-161.
6. Kawaguchi T, Yamagishi SI, and Sata M (2010). Structure-function relationships of PEDF. Curr Mol Med 10, 302-311.
7. Dass CR, Ek ET, and Choong PF (2008). PEDF as an emerging therapeutic candidate for osteosarcoma. Curr Cancer Drug Targets 8, 683-690.
8. Broadhead ML, Dass CR, and Choong PF (2009). In vitro and in vivo biological activity of PEDF against a range of tumors. Expert Opin Ther Targets 13, 1429-1438.
9. Simonovic M, Gettins PG, and Volz K (2001). Crystal structure of human PEDF, a potent anti-angiogenic and neurite growth-promoting factor. Proc Natl Acad Sci USA 98, 11131-11135.
10. Rosca EV, Koskimaki JE, Rivera CG, Pandey NB, Tamiz AP, and Popel AS (2011). Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol 12, 1101-1116.
11. Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA, Aymerich MS, Becerra SP, Yap R, Veliceasa D, et al. (2005). Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 65, 5144-5152.
12. Mirochnik Y, Aurora A, Schulze-Hoepfner FT, Deabes A, Shifrin V, Beckmann R, Polsky C, and Volpert OV (2009). Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth. Clin Cancer Res 15, 1655-1663.
13. Karagiannis ED and Popel AS (2008). A systematic methodology for proteomewide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci USA 105, 13775-13780.
14. Pertschy B, Schneider C, Gnadig M, Schafer T, Tollervey D, and Hurt E (2009). RNA helicase Prp43 and its co-factor Pfa1 promote 20 to 18 S rRNA processing catalyzed by the endonuclease Nob1. J Biol Chem 284, 35079-35091.
15. Zhang L, Tang Y, Tie Y, Tian C, Wang J, Dong Y, Sun Z, and He F (2007). The PH domain containing protein CKIP-1 binds to IFP35 and Nmi and is involved in cytokine signaling. Cell Signal 19, 932-944.
16. Kim MS, Oh JE, Min CK, Lee S, Chung NG, Yoo NJ, and Lee SH (2009). Mutational analysis of CASP10 gene in acute leukaemias and multiple myelomas. Pathology 41, 484-487.
17. Derleth C and Mayer IA (2010). Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer 10 suppl 1, E23-E31.
18. Banerjee S, Dowsett M, Ashworth A, and Martin LA (2007).Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4, 536-550.
19. Doyle DM and Miller KD (2008). Development of new targeted therapies for breast cancer. Cancer Treat Res 141, 119-134.
20. Jemal A, Center MM, De Santis C, and Ward EM (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19, 1893-1907.
21. Pal SK, Childs BH, and Pegram M (2011). Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125, 627-636.
22. Koskimaki JE, Karagiannis ED, Rosca EV, Vesuna F, Winnard PT Jr, Raman V, Bhujwalla ZM, and Popel AS (2009). Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia 11, 1285-1291.
23. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, and Davidson NE (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357, 2666-2676.
24. Schneider BP and Sledge GW Jr (2011). Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners? J Clin Oncol 29, 2444-2447.
25. Gilmore AP and Romer LH (1996). Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol Biol Cell 7, 1209-1224.
26. Ek ET, Dass CR, Contreras KG, and Choong PF (2007). PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma. J Orthop Res 25, 1671-1680.
27. Farina HG, Benavent Acero F, Perera Y, Rodriguez A, Perea SE, Castro BA, Gomez R, Alonso DF, and Gomez DE (2011). CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo. Exp Cell Res 317, 1677-1688.
28. Sulochana KN, Fan H, Jois S, Subramanian V, Sun F, Kini RM, and Ge R (2005). Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis. J Biol Chem 280, 27935-27948.
29. Salomonsson E, Thijssen VL, Griffioen AW, Nilsson UJ, and Leffler H (2011). The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins. J Biol Chem 286, 13801-13804.
30. Vlahopoulos S and Zoumpourlis VC (2004). JNK: a key modulator of intracellular signaling. Biochemistry (Mosc) 69, 844-854.
31. Konson A, Pradeep S, and Seger R (2010). Phosphomimetic mutants of pigment epithelium-derived factor with enhanced antiangiogenic activity as potent anticancer agents. Cancer Res 70, 6247-6257.